For example, while IDH1/2 mutations are common early alterations in gliomas, some research suggests that these mutations switch from driver to passenger mutations as disease progresses, potentially explaining observed resistance to IDH inhibitors (134). This evidence concerns the gene IDH1 and central nervous system cancer.